Endometriosis and menopausal health: An EMAS clinical guide.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert consensus statement without primary human data or systematic review methodology.
PubMed 40907339 · doi:10.1016/j.maturitas.2025.108715
What was done
The European Menopause and Andropause Society (EMAS) conducted a review of the literature and an expert consensus process to formulate a clinical guide for the assessment and management of menopausal health in women with a history of endometriosis.
What was found
The abstract reports no quantitative results, statistical estimates, or sample sizes. Key consensus recommendations include: surgical management is preferred for symptomatic postmenopausal endometriosis; continuous combined menopausal hormone therapy (MHT) is recommended over estrogen-only MHT—even in hysterectomized women—to lower risks of disease recurrence and malignant transformation; neurokinin-3 receptor antagonists are non-hormonal alternatives for vasomotor symptoms; bone health should be supported with antiresorptive or anabolic agents, calcium, and vitamin D; and herbal preparations should be avoided due to potential estrogenic effects.
Why it matters
It provides clinical guidance on postmenopausal hormone management for women with a history of endometriosis, notably advising against unopposed estrogen therapy even after hysterectomy.
Limits
This is an expert consensus and narrative clinical guide, not a systematic review or primary trial. The abstract provides no quantitative data, search protocol details, study counts, or patient numbers.
Cited by
- supports Postmenopausal estrogen replacement therapy without progesterone can reactivate residual endometriotic implants in patients with a history of endometriosis even after hysterectomy.